GSA Capital Partners LLP Takes Position in Omnicell, Inc. (NASDAQ:OMCL)

GSA Capital Partners LLP purchased a new position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,781 shares of the company's stock, valued at approximately $901,000. GSA Capital Partners LLP owned 0.06% of Omnicell as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Lazard Asset Management LLC increased its holdings in shares of Omnicell by 81.6% in the 4th quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock valued at $73,093,000 after acquiring an additional 737,536 shares during the period. Toronto Dominion Bank purchased a new position in shares of Omnicell in the 4th quarter valued at $30,637,000. Dimensional Fund Advisors LP increased its holdings in shares of Omnicell by 31.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock valued at $73,127,000 after acquiring an additional 394,820 shares during the period. Oberweis Asset Management Inc. purchased a new position in shares of Omnicell in the 4th quarter valued at $14,834,000. Finally, Pacer Advisors Inc. purchased a new position in shares of Omnicell in the 1st quarter valued at $10,542,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on OMCL shares. Wall Street Zen upgraded Omnicell from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 12th. Wells Fargo & Company lifted their price target on Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a report on Monday, July 21st. Piper Sandler reissued an "overweight" rating on shares of Omnicell in a research report on Friday, May 23rd. Benchmark lowered their price objective on Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, Bank of America raised their price objective on Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, May 23rd. Three analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $45.33.

Omnicell Stock Performance

Omnicell stock traded down $1.25 during trading hours on Friday, hitting $29.76. 742,476 shares of the stock traded hands, compared to its average volume of 500,803. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.23. The firm's 50 day moving average price is $29.27 and its 200-day moving average price is $33.18. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of 59.52, a P/E/G ratio of 9.05 and a beta of 0.76. Omnicell, Inc. has a 1 year low of $22.66 and a 1 year high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.30 by $0.15. The business had revenue of $290.56 million for the quarter, compared to the consensus estimate of $275.57 million. Omnicell had a return on equity of 4.27% and a net margin of 2.01%. The company's quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.51 EPS. As a group, equities analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.